Children's Hospital Affiliated to Shandong University, Department of Vascular Anomalies and Interventional Radiology, Jinan, China.
Children's Hospital Affiliated to Shandong University, Department of Vascular Anomalies and Interventional Radiology, Jinan, China; Jinan Children's Hospital, Department of Vascular Anomalies and Interventional Radiology, Jinan, China; Shandong Provincial Clinical Research Center for Children's Health and Disease, Jinan, China.
Braz J Otorhinolaryngol. 2023 Jul-Aug;89(4):101270. doi: 10.1016/j.bjorl.2023.03.007. Epub 2023 Mar 30.
This study aims to perform a meta-analysis to figure out the efficacy of OK-432 sclerotherapy between Macrocystic (MAC) lymphangiomas and Microcystic (MIC) lymphangiomas.
We conducted a systematic review and meta-analysis to clarify the relationship between OK-432 and lymphangiomas. PubMed and ISI Web of Science were searched from inception to May 2022. Joanna Briggs Institute (JBI) manual was used to evaluate the risk of bias. We calculated pooled Relative Risks (RR) and 95% Confidence Interval (95% CI) using random effects model to evaluate the relations between OK-432 and lymphangiomas.
A total of 11 studies (including 352 cases) about OK-432 sclerotherapy for lymphangioma were included in the current meta-analyses. The results suggested that the efficacy of OK-432 was significantly in MAC lesions than in MIC (RR=1.51, 95% CI 1.298-1.764), with significant moderate degrees of heterogeneity among 11 studies (I=51.2%, p=0.025). Subgroup analyses suggested that there was significant association in both retrospective studies (RR=1.26, 95% CI 1.03-1.53) and classification (by 1 cm) (RR=1.37, 95% CI 1.04-1.80) were associated with the efficacy of OK-432.
To our knowledge, our study represents the first meta-analysis examining the efficacy of OK-432 in the treatment of different types of LMs. However, the regional differences and the age differences of the subjects are the main limitations of this study and should be avoided in further research. Our results suggested that OK-432 sclerotherapy for macrocystic lymphangiomas was more effective.
本研究旨在进行荟萃分析，以明确 OK-432 硬化疗法治疗巨囊型（MAC）淋巴管瘤和微囊型（MIC）淋巴管瘤的疗效。
我们进行了系统评价和荟萃分析，以阐明 OK-432 与淋巴管瘤之间的关系。从建库到 2022 年 5 月，我们检索了 PubMed 和 ISI Web of Science。我们使用 Joanna Briggs Institute（JBI）手册评估偏倚风险。我们使用随机效应模型计算汇总相对风险（RR）和 95%置信区间（95%CI），以评估 OK-432 与淋巴管瘤之间的关系。
共有 11 项关于 OK-432 硬化疗法治疗淋巴管瘤的研究（包括 352 例）纳入本次荟萃分析。结果表明，OK-432 在 MAC 病变中的疗效明显优于 MIC（RR=1.51，95%CI 1.298-1.764），11 项研究之间存在显著的中度异质性（I=51.2%，p=0.025）。亚组分析表明，回顾性研究（RR=1.26，95%CI 1.03-1.53）和分类（按 1cm 分类）（RR=1.37，95%CI 1.04-1.80）均与 OK-432 的疗效显著相关。
据我们所知，本研究是首次荟萃分析检查 OK-432 治疗不同类型 LM 的疗效。然而，研究对象的地区差异和年龄差异是本研究的主要局限性，应在进一步研究中避免。我们的结果表明，OK-432 硬化疗法治疗巨囊型淋巴管瘤更有效。
